Cargando…
Turning biodefense dollars into products
Five years after the US anthrax attacks, and more than two years after BioShield legislation was ratified, a survey reveals that biodefense funding has thus far produced only a handful of products for clinical development.
Autores principales: | Trull, Melanie C, du Laney, Tracey V, Dibner, Mark D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097580/ https://www.ncbi.nlm.nih.gov/pubmed/17287749 http://dx.doi.org/10.1038/nbt0207-179 |
Ejemplares similares
-
Bioterrorism and biodefense
por: Artenstein, Andrew W.
Publicado: (2010) -
Bioterrorism and Biodefense
por: Artenstein, Andrew W.
Publicado: (2017) -
Mucosal Vaccines for Biodefense
por: Mantis, N. J., et al.
Publicado: (2011) -
Microfluidic Applications in Biodefense
por: Tian, Wei-Chang, et al.
Publicado: (2008) -
Biodefense versus bioterrorism
por: Petsko, Gregory A
Publicado: (2008)